WO1997024445A1 - Recombinant fusion proteins to growth hormone and serum albumin - Google Patents

Recombinant fusion proteins to growth hormone and serum albumin Download PDF

Info

Publication number
WO1997024445A1
WO1997024445A1 PCT/GB1996/003164 GB9603164W WO9724445A1 WO 1997024445 A1 WO1997024445 A1 WO 1997024445A1 GB 9603164 W GB9603164 W GB 9603164W WO 9724445 A1 WO9724445 A1 WO 9724445A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polypeptide according
hgh
region
amino acids
Prior art date
Application number
PCT/GB1996/003164
Other languages
French (fr)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Limited filed Critical Delta Biotechnology Limited
Priority to DK05077642T priority Critical patent/DK1681304T3/en
Priority to EP96942515A priority patent/EP0870039B1/en
Priority to DE69635903T priority patent/DE69635903T2/en
Priority to JP52409897A priority patent/JP4063878B2/en
Priority to AU11649/97A priority patent/AU715210B2/en
Priority to CA2240292A priority patent/CA2240292C/en
Priority to KR1019980704914A priority patent/KR19990076789A/en
Publication of WO1997024445A1 publication Critical patent/WO1997024445A1/en
Priority to US09/984,010 priority patent/US7045318B2/en
Priority to US11/315,035 priority patent/US7550432B2/en
Priority to US12/471,168 priority patent/US8642542B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to recombinant fusion proteins, to growth hormone (GH), to serum albumin and to production of proteins in yeast.
  • GH growth hormone
  • HSA Human serum albumin
  • rHA recombinant HA
  • albumin as a carrier molecule and its inert nature are desirable properties for use as a stabiliser and transporter of polypeptides.
  • the use of albumin as a component of a fusion protein for stabilising other proteins has been disclosed in WO 93/15199, WO 93/15200, and EP 413 622.
  • the use of N-terminal fragments of HSA for fusions to polypeptides has also been disclosed (EP 399 666). Fusion to the said polypeptide is achieved by genetic manipulation, such that the DNA coding for HSA, or a fragment thereof, is joined to the DNA coding for the said polypeptide.
  • a suitable host is then transformed or transfected wim the fused nucleotide sequences, so arranged on a suitable plasmid as to express a fusion polypeptide.
  • Nomura et al (1995) attempted to express human apolipoprotein E in S. cerevisiae as a fusion protein with HSA or fragments of HSA, using the HSA pre-sequence to direct secretion. Whilst fusion to full length HSA resulted in the secretion of low levels of the protein into the medium (maximum yield of 6.3 mg per litre), fusion to HSA (1-198) or HSA (1-390) did not result in secretion into the medium.
  • Human growth hormone (reviewed by Strobl and Thomas, 1994) consists of a single polypeptide of 191 amino acids, internally cross-linked by two disulphide bonds. Two molecules of hGH receptor bind each molecule of hGH to facilitate signal transduction (Cunningham et al, 1991; de Vos et al, 1992). The C-te ⁇ ninus of the hGH molecule is involved in binding to the first receptor molecule, but the extent to which the N-te ⁇ ninus is involved in receptor binding is not known. The hormone is secreted from the anterior pituitary gland under hypothalamic control, and is responsible for a wide range of growth-promoting effects in the body.
  • hGH is used in the treatment of hypopituitary dwarfism, chronic renal insufficiency in childhood, bone fractures and burns.
  • Current methods of production of hGH for therapeutic use are by extraction from human pituitary gland, recombinant expression in Escherichia coli as disclosed in EP 127 305 (Genentech) or recombinant expression in mammalian cell culture (Zeisel et al, 1992).
  • hGH has been expressed intracellularly in yeast (Tokunaga et al, 1985) and this organism may provide an alternative means of production as disclosed in EP 60 057 (Genentech).
  • Tsiomenko et al (1994) reported the role of the yeast MF ⁇ -1 prepro leader sequence in the secretion of hGH from yeast. Attachment of the pre-portion of the leader sequence to the hGH gene resulted in hGH accumulation in die periplasm and vacuoles, whilst attachment of the pro-portion to hGH resulted in expression of a non-glycosylated precursor localised inside the cell. Only when both portions of the leader sequence were attached to me hGH gene was hGH secreted into the culture medium. Other secretion signals (pre- sequences) were also ineffective unless a yeast-derived pro sequence was used, suggesting mat such a pro sequence was used is critical to the efficient secretion of hGH in yeast.
  • hGH is secreted into the blood in pulses, and in die circulation has a half-life of less than 20 minutes (Haffher et al, 1994). Elimination of the hormone is primarily via metabolism in the liver and kidneys and is more rapid in adults man in children (Kearns et al, 1991). Treatment for hGH deficiency generally lasts for 6 to 24 monms, during which hGH is administered either tiiree times a week intramuscularly or on a daily basis subcutaneously. Such a regimen of frequent adnamistration is necessary because of the short half-life of the molecule.
  • Poznansky et al (1988) increased the half-life of porcine growth hormone by conjugation with either porcine or human serum albumin (HSA) to form relatively large conjugates of about 180 kD.
  • Chemical reaction using me cross-linking reagent glutaraldehyde resulted in, on average, two molecules of albumin complexed with six molecules of growm hormone.
  • the resulting 180 kD conjugate was found to have an extended half-life in the circulation of rats of 2 to 3 hours, compared to 5 minutes for unco ⁇ jugated growm hormone.
  • Activity assays showed mat die conjugate retained full, and possibly increased activity in vitro, but was inactive in vivo.
  • the invention relates to proteins formed by the fusion of a molecule of albumin, or variants or fragments diereof, to a molecule of growth hormone or variants or fragments mereof, the fusion proteins having an increased circulatory half-life over unfused growtii hormone.
  • HA human albumin
  • hGH human growth hormone
  • the fusion protein comprises HA, or a variant or fragment tiiereof, as the N-terminal portion, with hGH or a variant or fragment tiiereof as the C-terminal portion, so as to minimise any possible negative effects on receptor binding.
  • a fusion protein comprising HA, or a variant or fragment thereof, as the C-terminal portion, with hGH or a variant or fragment thereof as the N- terminal portion, may also be capable of signal transduction.
  • the polypeptide has only one HA-derived region and one GH-derived region.
  • the fusion proteins of the invention may include a linker peptide between the two fused portions to provide a greater physical separation between the two moieties and thus maximise the availability of the hGH portion to bind the hGH receptor.
  • the linker peptide may consist of amino acids such that it is flexible or more rigid.
  • the linker sequence may be cleavable by a protease or chemically to yield the growth hormone related moiety.
  • the protease is one which is produced naturally by the host, for example the S. cerevisiae protease kex2 or equivalent proteases.
  • a further aspect of tlie invention provides a process for preparing growth hormone or a variant or fragment thereof by expressing a polynucleotide which encodes a polypeptide of the invention in a suitable host, cleaving the cleavable linker to yield the GH- type compound and recovering the GH-type compound from the host culture in a more pure form.
  • polypeptides of the invention are significantly more stable in solution than hGH.
  • the latter rapidly becomes inactive when stored in solution at 4°C for over one month.
  • hGH is sold as a freeze-dried powder.
  • the fusion polypeptides are produced as recombinant molecules by secretion from yeast, a microorganism such as a bacterium, human cell line or a yeast.
  • the polypeptide is secreted from the host.
  • yeast-derived pro sequence was needed for efficient secretion of hGH in yeast.
  • a particular embodiment of the invention comprises a DNA construct encoding a signal sequence effective for directing secretion in yeast, particularly a yeast-derived signal sequence (especially one which is homologous to the yeast host), and the fused molecule of the first aspect of the invention, there being no yeast-derived pro sequence between the signal and the mature polypeptide.
  • Saccharomyces cerevisiae invertase signal is a preferred example of a yeast-derived signal.
  • the albumin or hGH may be a variant of normal HSA/rHA (termed hereinafter "HA") or hGH, respectively.
  • variants we mclude insertions, deletions and substitutions, either conservative or non- conservative, where such changes do not substantially alter one or more of the oncotic, useful ligand-binding and non-immunogenic properties of albumin or, in the case of hGH, its non-immunogenicity and ability to bind and activate the hGH receptor.
  • HA normal HSA/rHA
  • hGH hGH
  • variants we include naturally- occurring polymorphic variants of human albumin and fragments of human albumin, for example those fragments disclosed in EP 322 094 (namely HA (1-n), where n is 369 to 419).
  • the albumin or growth hormone may be from any vertebrate, especially any mammal, for example human, cow, sheep, pig, hen or salmon.
  • the albumin and GH parts of the fusion may be from differ
  • HA variant By “conservative substitutions” is intended swaps within groups such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
  • the variant will usually have at least 75% (preferably at least 80%, 90%, 95% or 99%) sequence identity with a length of normal HA or hGH which is the same length as the variant and which is more identical thereto than any other length of normal HA or hGH, once the allowance is made for deletions and insertions as is customary in this art.
  • an HA variant will be at least 100 amino acids long, preferably at least 150 amino acids long.
  • the HA variant may consist of or comprise at least one whole domain of HA, for example domains 1 (1- 194), 2 (195-387), 3 (388-585), 1 + 2 (1-387), 2 + 3 (195-585) or 1 + 3 (1-194, + 388-585).
  • Each domain is itself made up of two homologous subdomains namely 1-105, 120-194, 195-291, 316-387, 388-491 and 512- 585, with flexible inter-subdomain linker regions comprising residues Lysl06 to Glul99, Glu292 to Val315 and Glu492 to Ala511.
  • the HA part of the fusion comprises at least one subdomain or domain of HA or conservative modifications thereof.
  • the fusion is based on subdomains, some or all of the adjacent linker is preferably used to link to the hGH moiety.
  • the hGH variant should have GH activity, and will generally have at least 10 amino acids, (although some authors have found activity with only 4 residues), preferably at least 20, preferably at least 50, 100, 150, 180 or 191, amino acids long, and preferably retains its cysteines for both internal disulphide bonds.
  • the fused molecules of the invention generally have a molecular weight of less than 100 kD, for example less than 90 kD or 70 kD. They are therefore much smaller than the 180 kD conjugates of Poznansky et al (referred to above), which were inactive in vivo. They will normally have a molecular weight of at least 20 kD, usually at least 30 kD or 50 kD. Most fall within the molecular weight range 60-90 kD.
  • a second main aspect of the invention provides a yeast transformed to express a fusion protein of the invention.
  • the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culmre derived from a monoclonal culture, in a nutrient medium.
  • a culture of those cells preferably a monoclonal (clonally homogeneous) culture, or a culmre derived from a monoclonal culture, in a nutrient medium.
  • the medium will thus contain the polypeptide, with the cells, or without the cells if they have been filtered or centrifuged away.
  • bacteria for example E. coli and Bacillus subtilis
  • yeasts for example Saccharomyces cerevisiae, Kluyveromyces lactis and Pichia pastoris
  • filamentous fungi for example Aspergillus
  • plant cells animal cells and insect cells.
  • the desired protein is produced in conventional ways, for example from a coding sequence inserted in the host chromosome or on a free plasmid.
  • yeasts are transformed with a coding sequence for the desired protein in any of the usual ways, for example electroporation. Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) Methods Enzymol. 194, 182.
  • Successfully transformed cells ie cells that contain a DNA construct of the present invention
  • cells resulting from the introduction of an expression construct can be grown to produce the desired polypeptide.
  • Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) J. Mol. Biol. 98, 503 or Berent et al (1985) Biotech. 3, 208.
  • the presence of the protein in the supernatant can be detected using antibodies.
  • Useful yeast plasmid vectors include pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA.
  • Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Yips) and incorporate the yeast selectable markers HIS3, TRPl, LEU2 and URA3.
  • Plasmids pRS413-416 are Yeast Centromere plasmids (YCps).
  • a variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.
  • Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors.
  • the DNA segment generated by endonuclease restriction digestion, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, 3 '-single-stranded termini with their 3'- 5'-exonucleolytic activities, and fill in recessed 3 '-ends with their polymerizing activities.
  • the combination of these activities therefore generates blunt-ended DNA segments.
  • the blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • the products of the reaction are DNA segments carrying polymeric linker sequences at their ends.
  • These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.
  • Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Ine, New Haven, CN, USA.
  • a desirable way to modify the DNA in accordance with the invention is to use the polymerase chain reaction as disclosed by Saiki et al (1988) Science 239, 487-491.
  • the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA.
  • the said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.
  • Exemplary genera of yeast contemplated to be useful in the practice of the present invention as hosts for expressing the fusion proteins are Pichia (Hansenula), Saccharomyces, Kluyveromyces, Candida, Torulopsis, Torulaspora, Schizosaccharomyces, Citeromyces, Pachysolen, Debaromyces, Metschunikowia, Rhodosporidium, Leucosporidium, Botryoascus, Sporidiobolus, Endomycopsis , and the like.
  • Preferred genera are those selected from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia and Torulaspora.
  • Saccharomyces spp. are S. cerevisiae, S. italicus and 5. rouxii.
  • Kluyveromyces spp. are K. fragilis, K. lactis and K. marxianus.
  • a suitable Torulaspora species is T. delbrueckii.
  • Examples of Pichia (Hansenula) spp. are P. angusta (formerly H. polymorph ⁇ ), P. anomala (formerly H. anomal ⁇ ) and P. pastoris.
  • Suitable promoters for S. cerevisiae include those associated with the PGKl gene, GALl or GAL10 genes, CYCI , PH05, TRPl , ADH1 , ADH2, the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase, glucokinase, ⁇ -mating factor pheromone, a- mating factor pheromone, the PRB1 promoter, the GUT2 promoter, the GPD1 promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (eg the promoter of EP-A-258 067).
  • Convenient regulatable promoters for use in Schizosaccharomyces pombe are the thiamine-repressible promoter from the nmt gene as described by Maundrell (1990) J. Biol. Chem. 265, 10857-10864 and the glucose- repressible fbpl gene promoter as described by Hoffman & Winston (1990) Genetics 124, 807-816.
  • Pichia expression kits are commercially available from Invitrogen BV, Leek, Netherlands, and Invitrogen Corp. , San Diego, California. Suitable promoters include AOX1 and AOX2.
  • Gleeson et al (1986) J. Gen. Microbiol. 132, 3459-3465 include information on Hansenula vectors and transformation, suitable promoters being MOX1 and FMD1; whilst EP 361 991 , Fleer et al (1991) and other publications from Rh ⁇ ne-Poulenc Rorer teach how to express foreign proteins in Kluyveromyces spp., a suitable promoter being PGKl.
  • the transcription termination signal is preferably the 3 ' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation.
  • Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, ie may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the S. cerevisiae ADH1 gene is preferred.
  • the desired fusion protein may be initially expressed witii a secretion leader sequence, which may be any leader effective in the yeast chosen.
  • Leaders useful in S. cerevisiae include that from the mating factor ⁇ polypeptide (MF ⁇ -1) and the hybrid leaders of EP-A-387 319.
  • Such leaders are cleaved by the yeast before the mature albumin is released into the surrounding medium.
  • Further such leaders include those of S. cerevisiae invertase (SUC2) disclosed in JP 62-096086 (granted as 91/036516), acid phosphatase (PH05), the pre-sequence of MF ⁇ -1, jS- glucanase (BGL2) and killer toxin; S. diastaticus glucoamylase II; S. carlsbergensis ⁇ -galactosidase (MELl); K. lactis killer toxin; and Candida glucoamylase.
  • SUC2 S. cerevisiae invertase
  • the fusion protein of the invention or a formulation thereof may be administered by any conventional method including parenteral (eg subcutaneous or intramuscular) injection or intravenous infusion.
  • the treatment may consist of a single dose or a plurality of doses over a period of time.
  • a fusion protein of the invention Whilst it is possible for a fusion protein of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the fusion protein and not deleterious to the recipients thereof.
  • the carriers will be water or saline which will be sterile and pyrogen free.
  • the formulation should be non-immunogenic; vaccine-type formulations involving adjuvants are not contemplated.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the fusion protein with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of an active ingredient.
  • the fusion proteins of the invention may be used in the treatment of any condition in which growth hormone is indicated, for example isolated growth hormone deficiency, panhypopituitarism, following cranial irradiation (eg in the treatment of leukaemia or brain tumours), Turner's syndrome, Down's syndrome, intrauterine growth retardation, idiopathic growth deficiency, chronic renal failure, achondroplasia, female infertility and various catabolic disorders. They may also be used in the stimulation of growth, and/or enhancement of lean meat proportion, in farm animals such as cows, sheep, goats and pigs.
  • the fusion protein may be administered together with insulin-like growth factor I (IGF-I).
  • IGF-I insulin-like growth factor I
  • the dosage can be calculated on the basis of the potency of the fusion protein relative to the potency of hGH, whilst taking into account the prolonged serum half-life of the fusion proteins compared to that of native hGH.
  • Growth hormone is typically administered at 0.3 to 30.0 IU/kg/week, for example 0.9 to 12.0 IU/kg/week, given in three or seven divided doses for a year or more.
  • an equivalent dose in terms of units would represent a greater weight of agent but the dosage frequency can be reduced, for example to twice a week, once a week or less.
  • Figure 1 shows the human growth hormone cDNA sequence, encoding mature hGH
  • Figure 2 shows a restriction enzyme map of pHGHl
  • Figure 3 shows a restriction enzyme map of pBST(+) and the DNA sequence of the polylinker
  • FIG. 4 shows the construction of pHGH12
  • Figure 5 shows the construction of pHGHl ⁇ ;
  • Figure 6 shows the HSA cDNA sequence, more particularly the region encoding the mature protein;
  • FIG. 7 shows the construction of pHGH14
  • FIG. 8 shows the construction of pHGH38
  • FIG. 9 shows the construction of pHGH31
  • FIG 10 shows the construction of pHGH58 or pHGH59 (Example 7);
  • Figure 11 is a scheme for constructing fusions having spacers (Example 7).
  • Figure 12 shows the results of a pharmacokinetic study showing the clearance of 125 I-labelled rHA-hGH compared to that of hGH following iv injection in rats. Data are from two rats in each group, and include total radioactivity and radioactivity which could be precipitated by TCA, ie that associated with protein rather than as free 125 I. The calculated clearance half-life for hGH was approximately 6 rainutes, compared to approximately 60 minutes for the rHA-hGH fusion protein. See Example 3.
  • Example 1 Cloning of the hGH cDNA.
  • the hGH cDNA was obtained from a human pituitary gland cDNA library (catalogue number HL1097v, Clontech Laboratories, Ine) by PCR amplification. Two oligonucleotides suitable for PCR amplification of the hGH cDNA, HGH1 and HGH2, were synthesised using an Applied Biosystems 380B Oligonucleotide Synthesiser.
  • HGHl 5' - CCCAAGAATTCCCTTATCCAGGC - 3 '
  • HGH2 5 ' - GGGAAGCTTAGAAGCCACAGGATCCCTCCACAG - 3 '
  • HGHl and HGH2 differed from the equivalent portion of the hGH cDNA sequence ( Figure 1, Martial et al, 1979) by two and three nucleotides, respectively, such that after PCR amplification an EcoRI site would be introduced to the 5' end of the cDNA and a BamHl site would be introduced into the 3' end of the cDNA.
  • HGH2 contained a HmdIII site immediately downstream of the hG ⁇ sequence.
  • PCR amplification using a Perkin-Elmer-Cetus Thermal Cycler 9600 and a Perkin-Elmer-Cetus PCR kit was performed using single-stranded DNA template isolated from the phage particles of the cDNA library as follows: 10 ⁇ L phage particles were lysed by the addition of 10 ⁇ L phage lysis buffer (280 ⁇ g/mL proteinase K in TE buffer) and incubation at 55°C for 15 min followed by 85°C for 15 min. After a 1 min incubation on ice, phage debris was pelleted by centrifugation at 14,000 rpm for 3 min.
  • 10 ⁇ L phage particles were lysed by the addition of 10 ⁇ L phage lysis buffer (280 ⁇ g/mL proteinase K in TE buffer) and incubation at 55°C for 15 min followed by 85°C for 15 min. After a 1 min incubation on ice, phage debris was pelleted by centrifug
  • the PCR mixture contained 6 ⁇ L of this DNA template, 0.1 ⁇ M of each primer and 200 ⁇ M of each deoxyribonucleotide. PCR was carried out for 30 cycles, denaturing at 94°C for 30 s, annealing at 65°C for 30 s and extending at 72°C for 30 s, increasing the extension time by 1 s per cycle. Analysis of the reaction by gel electrophoresis showed a single product of the expected size (589 base pairs).
  • the PCR product was purified using Wizard PCR Preps DNA Purification System (Promega Corp) and then digested with coRI and HmdIII. After further purification of the £e ⁇ RI-HmdIII fragment by gel electrophoresis, the product was cloned into pUC19 (GIBCO BRL) digested with EcoRI and HmdIII, to give p ⁇ G ⁇ l ( Figure 2). DNA sequencing of the £c ⁇ RI- Hmdlll region showed that the PCR product was identical in sequence to the hG ⁇ sequence (Martial et al, 1979), except at the 5' and 3' ends, where the £ ⁇ ?RI and BamHl sites had been introduced, respectively.
  • Example 2 Expression of the hG ⁇ cDNA.
  • the polylinker sequence of the phagemid pBluescribe ( + ) (Stratagene) was replaced by inserting an oligonucleotide linker, formed by annealing two 75-mer oligonucleotides, between the EcoRI and Hindlll sites to form pBST( + ) ( Figure 3).
  • the new polylinker included a unique Noil site (the full sequence in the region of the polylinker is given in Figure 3).
  • the Notl ⁇ SA expression cassette of pAYE309 (EP 431 880) comprising the PRB1 promoter, DNA encoding the ⁇ SA/MF ⁇ -1 hybrid leader sequence, DNA encoding HSA and the ADH1 terminator, was transferred to pBST(+) to form pHAl ( Figure 4).
  • the HSA coding sequence was removed from this plasmid by digestion with HmdIII followed by religation to form pHA2 ( Figure 4).
  • hGH cDNA Cloning of the hGH cDNA, as described in Example 1 , provided the hGH coding region lacking the pro-hGH sequence and the first 8 base pairs (bp) of the mature hGH sequence.
  • a yeast promoter, signal peptide and the first 8 bp of the hGH sequence were attached to the 5' end of the cloned hGH sequence as follows:
  • HmdIII-S/ ⁇ NI fragment from p ⁇ Al was attached to the 5' end of the £c ⁇ RI -HmdIII fragment from p ⁇ G ⁇ l via two synthetic oligonucleotides, ⁇ G ⁇ 3 and HGH4:
  • HGH3 5 ' - GATAAAGATTCCCAAC - 3 '
  • HGH4 5 ' - AATTGTTGGGAATCTTT - 3 '
  • the HmdIII fragment so formed was cloned into HmdIII-digested p ⁇ A2 to make pHGH2 ( Figure 4), such that the hGH cDNA was positioned downstream of the PRB1 promoter and HSA/MF ⁇ -1 fusion leader sequence (WO 90/01063).
  • This plasmid comprised the entire 2 ⁇ m plasmid to provide replication functions and the LEU2 gene for selection of transformants.
  • pHGH12 was introduced into S. cerevisiae DB1 (Sleep et al, 1990) by transformation and individual transformants were grown for 3 days at
  • Example 3 Cloning and expression of an HSA-hGH fusion protein.
  • the pHAl H dIII--9_?w36I fragment (containing most of the ⁇ SA cDNA) was joined to the p ⁇ G ⁇ l £c ⁇ RI-HmdIII fragment (containing most of the hG ⁇ cDNA) via two oligonucleotides, ⁇ G ⁇ 7 and HGH8:
  • HGH7 5 ' - TTAGGCTTATTCCCAAC - 3 '
  • HGH8 5 ' - AATTGTTGGGAATAAGCC - 3 '
  • pHGH16 was used to transform S. cerevisiae DB1 and supernatants of cultures were analysed as in Example 2. A predominant band was observed that had a molecular weight of approximately 88 kD, corresponding to the combined masses of HA and hGH.
  • the fusion protein was purified from culmre supernatant by cation exchange chromatography, followed by anion exchange and gel permeation chromatography . Analysis of the N-terminus of the protein by amino acid sequencing confirmed the presence of the expected albumin sequence.
  • the fusion molecule was more potent than hGH when the same number of units of activity (based on the above in vitro assay) were administered daily. Further experiments in which the fusion protein was administered once every four days showed a similar overall growth response to a daily administration of hGH.
  • S. cerevisiae invertase (SUC2) leader sequence replaced the sequence for the hybrid leader, such that the encoded leader and the junction with the HSA sequence were as follows:
  • this plasmid directed the expression and secretion of the fusion protein at a level similar to that obtained with pHGH16. Analysis of the N-terminus of the fusion protein indicated precise and efficient cleavage of the leader sequence from the mature protein.
  • Example 4 Cloning and expression of an hGH-HSA fusion protein.
  • the HSA cDNA was first altered by site-directed mutagenesis to introduce an EcoNl site near the 5' end of the coding region. This was done by the method of Kunkel et al (1987) using single-stranded DNA template prepared from pHAl and a synthetic oligonucleotide, LEU4:
  • HGH5 5 ' - GATCCTGTGGCTTCGATGCACACAAGA - 3 '
  • HGH6 5 ' - CTCTTGTGTGCATCGAAGCCACAG - 3 '
  • pHGH14 was used to transform S. cerevisiae DBl and supernatants of cultures were analysed as in Example 2. A predominant band was observed that had a molecular weight of approximately 88 kD, corresponding to the combined masses of hGH and HA. Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
  • the fusion protein was purified from culture supernatant by cation exchange chromatography, followed by anion exchange and gel permeation chromatography . Analysis of the N-terminus of the protein by amino acid sequencing confirmed the presence of the expected hGH sequence.
  • fusion protein retained hGH activity, but was significantly less potent than a fusion protein comprising full-length HA (1-585) as the N-terminal portion and hGH as the C-terminal portion, as described in Example 3.
  • Example 5 Construction of plasmids for the expression of hGH fusions to domains of HSA.
  • Fusion polypeptides were made in which the hGH molecule was fused to the first two domains of HA (residues 1 to 387). Fusion to the N- terminus of hGH was achieved by joining the pHAl Hin ⁇ lll-Sapl fragment, which contained most of the coding sequence for domains 1 and 2 of HA, to the pHGHl £c ⁇ RI-HmdIII fragment, via the oligonucleotides ⁇ G ⁇ 11 and ⁇ G ⁇ 12:
  • HGHll 5' - TGTGGAAGAGCCTCAGAATTTATTCCCAAC - 3'
  • HGH12 5 ' - AATTGTTGGGAATAAATTCTGAGGCTCTTCC - 3 '
  • the HmdIII fragment so formed was cloned into HmdIII-digested p ⁇ A2 to make pHGH37 (Fig 8) and the Notl expression cassette of this plasmid was cloned into ⁇ f ⁇ l-digested pSAC35.
  • the resulting plasmid, pHGH38 (Fig 8) contained an expression cassette that was found to direct secretion of the fusion polypeptide into the supernatant when transformed into S. cerevisiae DBl.
  • Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
  • the fusion protein was purified from culmre supernatant by cation exchange chromatography followed by gel permeation chromatography. In vivo studies with purified protein indicated that the circulatory half-life was longer than that of hGH, and similar to that of a fusion protein comprising full-length HA (1-585) as the N-terminal portion and hGH as the C-terminal portion, as described in Example 3. In vitro studies showed that the fusion protein retained hGH activity.
  • a fusion protein comprising the first domain of HA (residues 1-194) as the N-terminal portion and hGH as the C-terminal portion, was cloned and expressed in 5. cerevisiae DBl .
  • Western blotting of culmre supernatant using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
  • Example 6 Expression of hGH bv introducing a cleavage site between HSA and hGH.
  • HGH1 5 ' - TTAGGCTTAAGCTTGGATAAAAGATTCCCAAC - 3 '
  • HGHl5 5 ' - AATTGTTGGGAATCTTTTATCCAAGCTTAAGCC - 3 '
  • the two species had molecular weights of approximately 66 kD, corresponding to (full length) HA, and 22 kD, corresponding to (full length) hGH, indicating in vivo cleavage of the fusion protein by the Kex2 protease, or an equivalent activity.
  • Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two separate species.
  • N- terminal sequence analysis of the hGH moiety confirmed the precise and efficient cleavage from the HA moiety.
  • the hGH moiety was purified from culmre supernatant by anion exchange chromatography followed by gel permeation chromatography. In vitro studies with the purified hGH showed that the protein was active and fully potent.
  • fusion proteins comprising either the first domain of HA (residues 1-194) or the first two domains of HA (residues 1-387), followed by a sequence recognised by the Kex2p protease, followed by the hGH cDNA, were cloned and expressed in 5. cerevisiae DBl . Western blotting of culmre supernatant using anti-HSA and anti-hGH antisera confirmed the presence of the two separate species.
  • Flexible linkers comprising repeating units of [Gly-Gly-Gly-Gly-Ser] n , where n was either 2 or 3, were introduced between the HSA and hGH fusion protein by cloning of the oligonucleotides HGH16, HGH17, HGH18 and HGH19: HGHl6 :5' -TTAGGCTTAGGTGGCGGTGGATCCGGCGGTGGTGGATCTTTCCCA AC-3'
  • HGHl7 5' -AATTGTTGGGAAAGATCCACCACCGCCGGATCCACCGCCACCTAA GCC-3'
  • HGHl8 5'-TTAGGCTTAGGCGGTGGTGGATCTGGTGGCGGCGGATCTGGTGGC GGTGGATCCTTCCCAAC-3 '
  • HGHl9 5' -AATTGTTGGGAAGGATCCACCGCCACCAGATCCGCCGCCACCA GATCCACCACCGCCTAAGCC-3 '
  • Transformation of S.cerevisiae with pHGH58, pHGH59, pHGH62 and pHGH63 resulted in transformants that secreted the fusion polypeptides into the supernatant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Fusion proteins of albumin and growth hormone, or fusions of variants of either, are secreted well in yeast and have increased serum and storage stability.

Description

RECOMBINANT FUSION PROTEINS TO GROWTH HORMONE AND SERUM ALBUMIN
Field of the invention
The present invention relates to recombinant fusion proteins, to growth hormone (GH), to serum albumin and to production of proteins in yeast.
Background and prior art
Human serum albumin (HSA), a protein of 585 amino acids, is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HSA for clinical use is produced by extraction from human blood. The production of recombinant HA (rHA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.
The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a stabiliser and transporter of polypeptides. The use of albumin as a component of a fusion protein for stabilising other proteins has been disclosed in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HSA for fusions to polypeptides has also been disclosed (EP 399 666). Fusion to the said polypeptide is achieved by genetic manipulation, such that the DNA coding for HSA, or a fragment thereof, is joined to the DNA coding for the said polypeptide. A suitable host is then transformed or transfected wim the fused nucleotide sequences, so arranged on a suitable plasmid as to express a fusion polypeptide. Nomura et al (1995) attempted to express human apolipoprotein E in S. cerevisiae as a fusion protein with HSA or fragments of HSA, using the HSA pre-sequence to direct secretion. Whilst fusion to full length HSA resulted in the secretion of low levels of the protein into the medium (maximum yield of 6.3 mg per litre), fusion to HSA (1-198) or HSA (1-390) did not result in secretion into the medium.
Human growth hormone (reviewed by Strobl and Thomas, 1994) consists of a single polypeptide of 191 amino acids, internally cross-linked by two disulphide bonds. Two molecules of hGH receptor bind each molecule of hGH to facilitate signal transduction (Cunningham et al, 1991; de Vos et al, 1992). The C-teπninus of the hGH molecule is involved in binding to the first receptor molecule, but the extent to which the N-teπninus is involved in receptor binding is not known. The hormone is secreted from the anterior pituitary gland under hypothalamic control, and is responsible for a wide range of growth-promoting effects in the body. Clinically, hGH is used in the treatment of hypopituitary dwarfism, chronic renal insufficiency in childhood, bone fractures and burns. Current methods of production of hGH for therapeutic use are by extraction from human pituitary gland, recombinant expression in Escherichia coli as disclosed in EP 127 305 (Genentech) or recombinant expression in mammalian cell culture (Zeisel et al, 1992).
In addition, hGH has been expressed intracellularly in yeast (Tokunaga et al, 1985) and this organism may provide an alternative means of production as disclosed in EP 60 057 (Genentech). Tsiomenko et al (1994) reported the role of the yeast MFα-1 prepro leader sequence in the secretion of hGH from yeast. Attachment of the pre-portion of the leader sequence to the hGH gene resulted in hGH accumulation in die periplasm and vacuoles, whilst attachment of the pro-portion to hGH resulted in expression of a non-glycosylated precursor localised inside the cell. Only when both portions of the leader sequence were attached to me hGH gene was hGH secreted into the culture medium. Other secretion signals (pre- sequences) were also ineffective unless a yeast-derived pro sequence was used, suggesting mat such a pro sequence was used is critical to the efficient secretion of hGH in yeast.
In humans, hGH is secreted into the blood in pulses, and in die circulation has a half-life of less than 20 minutes (Haffher et al, 1994). Elimination of the hormone is primarily via metabolism in the liver and kidneys and is more rapid in adults man in children (Kearns et al, 1991). Treatment for hGH deficiency generally lasts for 6 to 24 monms, during which hGH is administered either tiiree times a week intramuscularly or on a daily basis subcutaneously. Such a regimen of frequent adnamistration is necessary because of the short half-life of the molecule.
Poznansky et al (1988) increased the half-life of porcine growth hormone by conjugation with either porcine or human serum albumin (HSA) to form relatively large conjugates of about 180 kD. Chemical reaction using me cross-linking reagent glutaraldehyde resulted in, on average, two molecules of albumin complexed with six molecules of growm hormone. The resulting 180 kD conjugate was found to have an extended half-life in the circulation of rats of 2 to 3 hours, compared to 5 minutes for uncoηjugated growm hormone. Activity assays showed mat die conjugate retained full, and possibly increased activity in vitro, but was inactive in vivo.
Summary of the invention
The invention relates to proteins formed by the fusion of a molecule of albumin, or variants or fragments diereof, to a molecule of growth hormone or variants or fragments mereof, the fusion proteins having an increased circulatory half-life over unfused growtii hormone. For convenience, we shall refer to human albumin (HA) and human growth hormone (hGH), but die albumin and growth hormones of other vertebrates are included also. Preferably, the fusion protein comprises HA, or a variant or fragment tiiereof, as the N-terminal portion, with hGH or a variant or fragment tiiereof as the C-terminal portion, so as to minimise any possible negative effects on receptor binding. Alternatively, a fusion protein comprising HA, or a variant or fragment thereof, as the C-terminal portion, with hGH or a variant or fragment thereof as the N- terminal portion, may also be capable of signal transduction. Generally, the polypeptide has only one HA-derived region and one GH-derived region.
Additionally, the fusion proteins of the invention may include a linker peptide between the two fused portions to provide a greater physical separation between the two moieties and thus maximise the availability of the hGH portion to bind the hGH receptor. The linker peptide may consist of amino acids such that it is flexible or more rigid.
The linker sequence may be cleavable by a protease or chemically to yield the growth hormone related moiety. Preferably, the protease is one which is produced naturally by the host, for example the S. cerevisiae protease kex2 or equivalent proteases. Hence, a further aspect of tlie invention provides a process for preparing growth hormone or a variant or fragment thereof by expressing a polynucleotide which encodes a polypeptide of the invention in a suitable host, cleaving the cleavable linker to yield the GH- type compound and recovering the GH-type compound from the host culture in a more pure form.
We have discovered that the polypeptides of the invention are significantly more stable in solution than hGH. The latter rapidly becomes inactive when stored in solution at 4°C for over one month. Currently marketed hGH is sold as a freeze-dried powder.
Suitably, the fusion polypeptides are produced as recombinant molecules by secretion from yeast, a microorganism such as a bacterium, human cell line or a yeast. Preferably, the polypeptide is secreted from the host. We have found that, by fusing the hGH coding sequence to the HA coding sequence, either to the 5' end or 3' end, it is possible to secrete the fusion protein from yeast without the requirement for a yeast-derived pro sequence. This was surprising, as other workers have found that a yeast derived pro sequence was needed for efficient secretion of hGH in yeast. For example, Hiramitsu et al (1990, 1991) found that the N-teπninal portion of the pro sequence in the Mucor pusillus rennin pre-pro leader was important. Other authors, using the MFα-1 signal, have always included the MFα-1 pro sequence when secreting hGH. The pro sequences were believed to assist in the folding of the hGH by acting as an intramolecular chaperone. The present mvention shows that HA or fragments of HA can perform a similar function.
Hence, a particular embodiment of the invention comprises a DNA construct encoding a signal sequence effective for directing secretion in yeast, particularly a yeast-derived signal sequence (especially one which is homologous to the yeast host), and the fused molecule of the first aspect of the invention, there being no yeast-derived pro sequence between the signal and the mature polypeptide.
The Saccharomyces cerevisiae invertase signal is a preferred example of a yeast-derived signal.
Conjugates of the kind prepared by Poznansky et al (1988), in which separately-prepared polypeptides are joined by chemical cross-linking, are not contemplated.
The albumin or hGH may be a variant of normal HSA/rHA (termed hereinafter "HA") or hGH, respectively. By "variants" we mclude insertions, deletions and substitutions, either conservative or non- conservative, where such changes do not substantially alter one or more of the oncotic, useful ligand-binding and non-immunogenic properties of albumin or, in the case of hGH, its non-immunogenicity and ability to bind and activate the hGH receptor. In particular, we include naturally- occurring polymorphic variants of human albumin and fragments of human albumin, for example those fragments disclosed in EP 322 094 (namely HA (1-n), where n is 369 to 419). The albumin or growth hormone may be from any vertebrate, especially any mammal, for example human, cow, sheep, pig, hen or salmon. The albumin and GH parts of the fusion may be from differing animals.
By "conservative substitutions" is intended swaps within groups such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr. The variant will usually have at least 75% (preferably at least 80%, 90%, 95% or 99%) sequence identity with a length of normal HA or hGH which is the same length as the variant and which is more identical thereto than any other length of normal HA or hGH, once the allowance is made for deletions and insertions as is customary in this art. Generally speaking, an HA variant will be at least 100 amino acids long, preferably at least 150 amino acids long. The HA variant may consist of or comprise at least one whole domain of HA, for example domains 1 (1- 194), 2 (195-387), 3 (388-585), 1 + 2 (1-387), 2 + 3 (195-585) or 1 + 3 (1-194, + 388-585). Each domain is itself made up of two homologous subdomains namely 1-105, 120-194, 195-291, 316-387, 388-491 and 512- 585, with flexible inter-subdomain linker regions comprising residues Lysl06 to Glul99, Glu292 to Val315 and Glu492 to Ala511. Preferably, the HA part of the fusion comprises at least one subdomain or domain of HA or conservative modifications thereof. If the fusion is based on subdomains, some or all of the adjacent linker is preferably used to link to the hGH moiety. The hGH variant should have GH activity, and will generally have at least 10 amino acids, (although some authors have found activity with only 4 residues), preferably at least 20, preferably at least 50, 100, 150, 180 or 191, amino acids long, and preferably retains its cysteines for both internal disulphide bonds.
The fused molecules of the invention generally have a molecular weight of less than 100 kD, for example less than 90 kD or 70 kD. They are therefore much smaller than the 180 kD conjugates of Poznansky et al (referred to above), which were inactive in vivo. They will normally have a molecular weight of at least 20 kD, usually at least 30 kD or 50 kD. Most fall within the molecular weight range 60-90 kD.
A second main aspect of the invention provides a yeast transformed to express a fusion protein of the invention.
In addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culmre derived from a monoclonal culture, in a nutrient medium. Especially if the polypeptide is secreted, the medium will thus contain the polypeptide, with the cells, or without the cells if they have been filtered or centrifuged away.
Many expression systems are known, including bacteria (for example E. coli and Bacillus subtilis), yeasts (for example Saccharomyces cerevisiae, Kluyveromyces lactis and Pichia pastoris, filamentous fungi (for example Aspergillus), plant cells, animal cells and insect cells.
The desired protein is produced in conventional ways, for example from a coding sequence inserted in the host chromosome or on a free plasmid.
The yeasts are transformed with a coding sequence for the desired protein in any of the usual ways, for example electroporation. Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) Methods Enzymol. 194, 182.
Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct can be grown to produce the desired polypeptide. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) J. Mol. Biol. 98, 503 or Berent et al (1985) Biotech. 3, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.
Useful yeast plasmid vectors include pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Yips) and incorporate the yeast selectable markers HIS3, TRPl, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps).
A variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.
Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, 3 '-single-stranded termini with their 3'- 5'-exonucleolytic activities, and fill in recessed 3 '-ends with their polymerizing activities.
The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.
Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Ine, New Haven, CN, USA.
A desirable way to modify the DNA in accordance with the invention, if, for example, HA variants are to be prepared, is to use the polymerase chain reaction as disclosed by Saiki et al (1988) Science 239, 487-491. In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.
Exemplary genera of yeast contemplated to be useful in the practice of the present invention as hosts for expressing the fusion proteins are Pichia (Hansenula), Saccharomyces, Kluyveromyces, Candida, Torulopsis, Torulaspora, Schizosaccharomyces, Citeromyces, Pachysolen, Debaromyces, Metschunikowia, Rhodosporidium, Leucosporidium, Botryoascus, Sporidiobolus, Endomycopsis , and the like. Preferred genera are those selected from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia and Torulaspora. Examples of Saccharomyces spp. are S. cerevisiae, S. italicus and 5. rouxii. Examples of Kluyveromyces spp. are K. fragilis, K. lactis and K. marxianus. A suitable Torulaspora species is T. delbrueckii. Examples of Pichia (Hansenula) spp. are P. angusta (formerly H. polymorphά), P. anomala (formerly H. anomalά) and P. pastoris.
Methods for the transformation of S. cerevisiae are taught generally in EP 251 744, EP 258 067 and WO 90/01063, all of which are incorporated herein by reference.
Suitable promoters for S. cerevisiae include those associated with the PGKl gene, GALl or GAL10 genes, CYCI , PH05, TRPl , ADH1 , ADH2, the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase, glucokinase, α-mating factor pheromone, a- mating factor pheromone, the PRB1 promoter, the GUT2 promoter, the GPD1 promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (eg the promoter of EP-A-258 067).
Convenient regulatable promoters for use in Schizosaccharomyces pombe are the thiamine-repressible promoter from the nmt gene as described by Maundrell (1990) J. Biol. Chem. 265, 10857-10864 and the glucose- repressible fbpl gene promoter as described by Hoffman & Winston (1990) Genetics 124, 807-816.
Methods of transforming Pichia for expression of foreign genes are taught in, for example, Cregg et al (1993), and various Phillips patents (eg US 4 857 467, incorporated herein by reference), and Pichia expression kits are commercially available from Invitrogen BV, Leek, Netherlands, and Invitrogen Corp. , San Diego, California. Suitable promoters include AOX1 and AOX2.
Gleeson et al (1986) J. Gen. Microbiol. 132, 3459-3465 include information on Hansenula vectors and transformation, suitable promoters being MOX1 and FMD1; whilst EP 361 991 , Fleer et al (1991) and other publications from Rhόne-Poulenc Rorer teach how to express foreign proteins in Kluyveromyces spp., a suitable promoter being PGKl.
The transcription termination signal is preferably the 3 ' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, ie may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the S. cerevisiae ADH1 gene is preferred. The desired fusion protein may be initially expressed witii a secretion leader sequence, which may be any leader effective in the yeast chosen. Leaders useful in S. cerevisiae include that from the mating factor α polypeptide (MFα-1) and the hybrid leaders of EP-A-387 319. Such leaders (or signals) are cleaved by the yeast before the mature albumin is released into the surrounding medium. Further such leaders include those of S. cerevisiae invertase (SUC2) disclosed in JP 62-096086 (granted as 91/036516), acid phosphatase (PH05), the pre-sequence of MFα-1, jS- glucanase (BGL2) and killer toxin; S. diastaticus glucoamylase II; S. carlsbergensis α-galactosidase (MELl); K. lactis killer toxin; and Candida glucoamylase.
The fusion protein of the invention or a formulation thereof may be administered by any conventional method including parenteral (eg subcutaneous or intramuscular) injection or intravenous infusion. The treatment may consist of a single dose or a plurality of doses over a period of time.
Whilst it is possible for a fusion protein of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the fusion protein and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free. The formulation should be non-immunogenic; vaccine-type formulations involving adjuvants are not contemplated.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the fusion protein with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders.
Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of an active ingredient.
The fusion proteins of the invention may be used in the treatment of any condition in which growth hormone is indicated, for example isolated growth hormone deficiency, panhypopituitarism, following cranial irradiation (eg in the treatment of leukaemia or brain tumours), Turner's syndrome, Down's syndrome, intrauterine growth retardation, idiopathic growth deficiency, chronic renal failure, achondroplasia, female infertility and various catabolic disorders. They may also be used in the stimulation of growth, and/or enhancement of lean meat proportion, in farm animals such as cows, sheep, goats and pigs.
The fusion protein may be administered together with insulin-like growth factor I (IGF-I).
The dosage can be calculated on the basis of the potency of the fusion protein relative to the potency of hGH, whilst taking into account the prolonged serum half-life of the fusion proteins compared to that of native hGH. Growth hormone is typically administered at 0.3 to 30.0 IU/kg/week, for example 0.9 to 12.0 IU/kg/week, given in three or seven divided doses for a year or more. In a fusion protein consisting of full length HA fused to full length GH, an equivalent dose in terms of units would represent a greater weight of agent but the dosage frequency can be reduced, for example to twice a week, once a week or less.
Preferred examples of the invention will now be described by way of example and with reference to the accompanying figures, in which:
Figure 1 shows the human growth hormone cDNA sequence, encoding mature hGH;
Figure 2 shows a restriction enzyme map of pHGHl;
Figure 3 shows a restriction enzyme map of pBST(+) and the DNA sequence of the polylinker;
Figure 4 shows the construction of pHGH12;
Figure 5 shows the construction of pHGHlό; Figure 6 shows the HSA cDNA sequence, more particularly the region encoding the mature protein;
Figure 7 shows the construction of pHGH14;
Figure 8 shows the construction of pHGH38;
Figure 9 shows the construction of pHGH31;
Figure 10 shows the construction of pHGH58 or pHGH59 (Example 7);
Figure 11 is a scheme for constructing fusions having spacers (Example 7); and
Figure 12 shows the results of a pharmacokinetic study showing the clearance of 125I-labelled rHA-hGH compared to that of hGH following iv injection in rats. Data are from two rats in each group, and include total radioactivity and radioactivity which could be precipitated by TCA, ie that associated with protein rather than as free 125I. The calculated clearance half-life for hGH was approximately 6 rainutes, compared to approximately 60 minutes for the rHA-hGH fusion protein. See Example 3.
• - hGH (total counts) ■ - hGH (TCA precipitated counts) T - rHA-hGH (total counts) ▲ - rHA-hGH (TCA precipitated counts). Detailed description of the invention
All standard recombinant DNA procedures are as described in Sambrook et al (1989) unless otherwise stated. The DNA sequences encoding HSA were derived from the cDNA disclosed in EP 201 239.
Example 1: Cloning of the hGH cDNA.
The hGH cDNA was obtained from a human pituitary gland cDNA library (catalogue number HL1097v, Clontech Laboratories, Ine) by PCR amplification. Two oligonucleotides suitable for PCR amplification of the hGH cDNA, HGH1 and HGH2, were synthesised using an Applied Biosystems 380B Oligonucleotide Synthesiser.
HGHl: 5' - CCCAAGAATTCCCTTATCCAGGC - 3 '
HGH2 : 5 ' - GGGAAGCTTAGAAGCCACAGGATCCCTCCACAG - 3 '
HGHl and HGH2 differed from the equivalent portion of the hGH cDNA sequence (Figure 1, Martial et al, 1979) by two and three nucleotides, respectively, such that after PCR amplification an EcoRI site would be introduced to the 5' end of the cDNA and a BamHl site would be introduced into the 3' end of the cDNA. In addition, HGH2 contained a HmdIII site immediately downstream of the hGΗ sequence.
PCR amplification using a Perkin-Elmer-Cetus Thermal Cycler 9600 and a Perkin-Elmer-Cetus PCR kit, was performed using single-stranded DNA template isolated from the phage particles of the cDNA library as follows: 10 μL phage particles were lysed by the addition of 10 μL phage lysis buffer (280 μg/mL proteinase K in TE buffer) and incubation at 55°C for 15 min followed by 85°C for 15 min. After a 1 min incubation on ice, phage debris was pelleted by centrifugation at 14,000 rpm for 3 min. The PCR mixture contained 6 μL of this DNA template, 0.1 μM of each primer and 200 μM of each deoxyribonucleotide. PCR was carried out for 30 cycles, denaturing at 94°C for 30 s, annealing at 65°C for 30 s and extending at 72°C for 30 s, increasing the extension time by 1 s per cycle. Analysis of the reaction by gel electrophoresis showed a single product of the expected size (589 base pairs).
The PCR product was purified using Wizard PCR Preps DNA Purification System (Promega Corp) and then digested with coRI and HmdIII. After further purification of the £eøRI-HmdIII fragment by gel electrophoresis, the product was cloned into pUC19 (GIBCO BRL) digested with EcoRI and HmdIII, to give pΗGΗl (Figure 2). DNA sequencing of the £cøRI- Hmdlll region showed that the PCR product was identical in sequence to the hGΗ sequence (Martial et al, 1979), except at the 5' and 3' ends, where the £α?RI and BamHl sites had been introduced, respectively.
Example 2: Expression of the hGΗ cDNA.
The polylinker sequence of the phagemid pBluescribe ( + ) (Stratagene) was replaced by inserting an oligonucleotide linker, formed by annealing two 75-mer oligonucleotides, between the EcoRI and Hindlll sites to form pBST( + ) (Figure 3). The new polylinker included a unique Noil site (the full sequence in the region of the polylinker is given in Figure 3).
The Notl ΗSA expression cassette of pAYE309 (EP 431 880) comprising the PRB1 promoter, DNA encoding the ΗSA/MFα-1 hybrid leader sequence, DNA encoding HSA and the ADH1 terminator, was transferred to pBST(+) to form pHAl (Figure 4). The HSA coding sequence was removed from this plasmid by digestion with HmdIII followed by religation to form pHA2 (Figure 4).
Cloning of the hGH cDNA, as described in Example 1 , provided the hGH coding region lacking the pro-hGH sequence and the first 8 base pairs (bp) of the mature hGH sequence. In order to construct an expression plasmid for secretion of hGH from yeast, a yeast promoter, signal peptide and the first 8 bp of the hGH sequence were attached to the 5' end of the cloned hGH sequence as follows:
The HmdIII-S/αNI fragment from pΗAl was attached to the 5' end of the £cøRI -HmdIII fragment from pΗGΗl via two synthetic oligonucleotides, ΗGΗ3 and HGH4:
HGH3 : 5 ' - GATAAAGATTCCCAAC - 3 ' HGH4 : 5 ' - AATTGTTGGGAATCTTT - 3 '
The HmdIII fragment so formed was cloned into HmdIII-digested pΗA2 to make pHGH2 (Figure 4), such that the hGH cDNA was positioned downstream of the PRB1 promoter and HSA/MFα-1 fusion leader sequence (WO 90/01063). The Notl expression cassette contained in pHGH2, which included the ADH1 terminator downstream of the hGH cDNA, was cloned into Notl -digested pSAC35 (Sleep et al, 1990) to make pHGH12 (Figure 4). This plasmid comprised the entire 2μm plasmid to provide replication functions and the LEU2 gene for selection of transformants.
pHGH12 was introduced into S. cerevisiae DB1 (Sleep et al, 1990) by transformation and individual transformants were grown for 3 days at
30°C in 10 mL YEPD (1 % w/v yeast extract, 2% w/v peptone, 2% w/v dextrose). After centrifugation of the cells, the supernatants were examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and were found to contain protein which was of the expected size and which was recognised by anti-hGH antiserum (Sigma, Poole, UK) on Western blots.
Example 3: Cloning and expression of an HSA-hGH fusion protein.
In order to fuse the HSA cDNA to the 5' end of the hGH cDNA, the pHAl H dIII--9_?w36I fragment (containing most of the ΗSA cDNA) was joined to the pΗGΗl £cøRI-HmdIII fragment (containing most of the hGΗ cDNA) via two oligonucleotides, ΗGΗ7 and HGH8:
HGH7: 5 ' - TTAGGCTTATTCCCAAC - 3 ' HGH8 : 5 ' - AATTGTTGGGAATAAGCC - 3 '
The HmdIII fragment so formed was cloned into pΗA2 digested with HmdIII to make pΗGΗlO (Figure 5), and the Notl expression cassette of this plasmid was cloned into Nø/I-digested pSAC35 to make pΗGΗ16 (Figure 5).
pHGH16 was used to transform S. cerevisiae DB1 and supernatants of cultures were analysed as in Example 2. A predominant band was observed that had a molecular weight of approximately 88 kD, corresponding to the combined masses of HA and hGH. Western blotting using anti-HSA and anti-hGH antisera (Sigma) confirmed the presence of the two constituent parts of the fusion protein.
The fusion protein was purified from culmre supernatant by cation exchange chromatography, followed by anion exchange and gel permeation chromatography . Analysis of the N-terminus of the protein by amino acid sequencing confirmed the presence of the expected albumin sequence.
An in vitro growth hormone activity assay (Ealey et al, 1995) indicated that the fusion protein possessed full hGH activity, but that the potency was reduced compared to the hGH standard. In a hypophysectomised rat weight gain model, performed essentially as described in the European
Pharmacopoeia (1987, monograph 556), the fusion molecule was more potent than hGH when the same number of units of activity (based on the above in vitro assay) were administered daily. Further experiments in which the fusion protein was administered once every four days showed a similar overall growth response to a daily administration of hGH.
Pharmacokinetic experiments in which 125I-labelled protein was administered to rats indicated an approximately ten-fold increase in circulatory half life for the fusion protein compared to hGH (Fig 12).
A similar plasmid was constructed in which DNA encoding the S. cerevisiae invertase (SUC2) leader sequence replaced the sequence for the hybrid leader, such that the encoded leader and the junction with the HSA sequence were as follows:
MLLQAFLFLLAGFAAKISA I DAHKS.... Invertase leader HSA
On introduction into S. cerevisiae DBl, this plasmid directed the expression and secretion of the fusion protein at a level similar to that obtained with pHGH16. Analysis of the N-terminus of the fusion protein indicated precise and efficient cleavage of the leader sequence from the mature protein. Example 4: Cloning and expression of an hGH-HSA fusion protein.
In order to fuse the hGH cDNA to the 5' end of the HSA cDNA (Figure 6), the HSA cDNA was first altered by site-directed mutagenesis to introduce an EcoNl site near the 5' end of the coding region. This was done by the method of Kunkel et al (1987) using single-stranded DNA template prepared from pHAl and a synthetic oligonucleotide, LEU4:
LEU4 : 5 ' - GAGATGCACACCTGAGTGAGG
Site-directed mutagenesis using this oligonucleotide changed the coding sequence of the HSA cDNA from Lys4 to Leu4 (K4L). However, this change was repaired when the hGH cDNA was subsequently joined at the 5' end by linking the pHGH2 Notl-Bamrll fragment to the EcoNl-Notl fragment of the mutated pHAl , via the two oligonucleotides HGH5 and HGH6:
HGH5 : 5 ' - GATCCTGTGGCTTCGATGCACACAAGA - 3 ' HGH6 : 5 ' - CTCTTGTGTGCATCGAAGCCACAG - 3 '
The Notl fragment so formed was cloned into /Votl-digested pSAC35 to make pHGH14 (Figure 7). pHGH14 was used to transform S. cerevisiae DBl and supernatants of cultures were analysed as in Example 2. A predominant band was observed that had a molecular weight of approximately 88 kD, corresponding to the combined masses of hGH and HA. Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
The fusion protein was purified from culture supernatant by cation exchange chromatography, followed by anion exchange and gel permeation chromatography . Analysis of the N-terminus of the protein by amino acid sequencing confirmed the presence of the expected hGH sequence.
In vitro studies showed that the fusion protein retained hGH activity, but was significantly less potent than a fusion protein comprising full-length HA (1-585) as the N-terminal portion and hGH as the C-terminal portion, as described in Example 3.
Example 5: Construction of plasmids for the expression of hGH fusions to domains of HSA.
Fusion polypeptides were made in which the hGH molecule was fused to the first two domains of HA (residues 1 to 387). Fusion to the N- terminus of hGH was achieved by joining the pHAl Hinάlll-Sapl fragment, which contained most of the coding sequence for domains 1 and 2 of HA, to the pHGHl £cøRI-HmdIII fragment, via the oligonucleotides ΗGΗ11 and ΗGΗ12:
HGHll: 5' - TGTGGAAGAGCCTCAGAATTTATTCCCAAC - 3' HGH12 : 5 ' - AATTGTTGGGAATAAATTCTGAGGCTCTTCC - 3 '
The HmdIII fragment so formed was cloned into HmdIII-digested pΗA2 to make pHGH37 (Fig 8) and the Notl expression cassette of this plasmid was cloned into Λføl-digested pSAC35. The resulting plasmid, pHGH38 (Fig 8), contained an expression cassette that was found to direct secretion of the fusion polypeptide into the supernatant when transformed into S. cerevisiae DBl. Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
The fusion protein was purified from culmre supernatant by cation exchange chromatography followed by gel permeation chromatography. In vivo studies with purified protein indicated that the circulatory half-life was longer than that of hGH, and similar to that of a fusion protein comprising full-length HA (1-585) as the N-terminal portion and hGH as the C-terminal portion, as described in Example 3. In vitro studies showed that the fusion protein retained hGH activity.
Using a similar strategy as detailed above, a fusion protein comprising the first domain of HA (residues 1-194) as the N-terminal portion and hGH as the C-terminal portion, was cloned and expressed in 5. cerevisiae DBl . Western blotting of culmre supernatant using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion protein.
Example 6: Expression of hGH bv introducing a cleavage site between HSA and hGH.
Introduction of a peptide sequence that is recognised by the Kex2 protease, between the HA-hGH fusion protein, allows secretion of hGH. A sequence encoding Ser Leu Asp Lys Arg was introduced using two oligonucleotides, HGH14 and HGH15:
HGH1 : 5 ' - TTAGGCTTAAGCTTGGATAAAAGATTCCCAAC - 3 ' HGHl5 : 5 ' - AATTGTTGGGAATCTTTTATCCAAGCTTAAGCC - 3 '
These were used to join the pHAl Hinάlll-Bsuiβl fragment to the pΗGΗl
ZscøRI-H dlll fragment, which were then cloned into HmdIII-digested pΗA2 to make pHGH25 (Fig 9). The Notl expression cassette of this plasmid was cloned into Nørl-digested pSAC35 to make pHGH31 (Figure 9). S. cerevisiae DBl transformed with pHGH31 was found to secrete two major species, as determined by SDS-PAGE analysis of culture supernatants. The two species had molecular weights of approximately 66 kD, corresponding to (full length) HA, and 22 kD, corresponding to (full length) hGH, indicating in vivo cleavage of the fusion protein by the Kex2 protease, or an equivalent activity. Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two separate species. N- terminal sequence analysis of the hGH moiety confirmed the precise and efficient cleavage from the HA moiety.
The hGH moiety was purified from culmre supernatant by anion exchange chromatography followed by gel permeation chromatography. In vitro studies with the purified hGH showed that the protein was active and fully potent.
Using a similar strategy, fusion proteins comprising either the first domain of HA (residues 1-194) or the first two domains of HA (residues 1-387), followed by a sequence recognised by the Kex2p protease, followed by the hGH cDNA, were cloned and expressed in 5. cerevisiae DBl . Western blotting of culmre supernatant using anti-HSA and anti-hGH antisera confirmed the presence of the two separate species.
Example 7; Fusion of HSA to hGH using a flexible linker sequence
Flexible linkers, comprising repeating units of [Gly-Gly-Gly-Gly-Ser]n, where n was either 2 or 3, were introduced between the HSA and hGH fusion protein by cloning of the oligonucleotides HGH16, HGH17, HGH18 and HGH19: HGHl6 :5' -TTAGGCTTAGGTGGCGGTGGATCCGGCGGTGGTGGATCTTTCCCA AC-3'
HGHl7 : 5' -AATTGTTGGGAAAGATCCACCACCGCCGGATCCACCGCCACCTAA GCC-3' HGHl8:5'-TTAGGCTTAGGCGGTGGTGGATCTGGTGGCGGCGGATCTGGTGGC GGTGGATCCTTCCCAAC-3 '
HGHl9 : 5' -AATTGTTGGGAAGGATCCACCGCCACCAGATCCGCCGCCACCA GATCCACCACCGCCTAAGCC-3 '
Annealing of HGH16 with HGH17 resulted in n=2, while HGH18 annealed to HGH19 resulted in n=3. After annealing, the double-stranded oligonucleotides were cloned with the EcόRl-Bsuiβl fragment isolated from pHGHl into i3sH36I-digested pHGHIO to make pHGH56 (where n=2) and pHGH57 (where n=3) (Figure 10). The Notl expression cassettes from these plasmids were cloned into Notl-digested pSAC35 to make pHGH58 and pHGH59, respectively.
Cloning of the oligonucleotides to make pHGH56 and pHGH57 introduced a BamHl site in the linker sequences, as shown in Figure 11. It was therefore possible to construct linker sequences in which n= l and n=4, by joining either the H dlll-ZfomHI fragment from pHGH56 to the Sα HI-Hmdlll fragment from pΗGΗ57 (making n= l), or the Hmdlll- BamHl fragment from pΗGΗ57 to the BαmHI-HmdIII fragment from pΗGΗ56 (making n=2). Cloning of these fragments into the HmdIII site of pΗA2 (described in Example 2), resulted in pHGH60 (n= l) and pHGH61 (n=4) (see Figure 11). The Noil expression cassettes from pHGH60 and pHGH61 were cloned into /V -digested pSAC35 to make pHGH62 and pHGH63, respectively.
Transformation of S.cerevisiae with pHGH58, pHGH59, pHGH62 and pHGH63 resulted in transformants that secreted the fusion polypeptides into the supernatant.
Western blotting using anti-HSA and anti-hGH antisera confirmed the presence of the two constituent parts of the fusion proteins.
The fusion proteins were purified from culmre supernatant by cation exchange chromatography, followed by anion exchange and gel permeation chromatography. Analysis of the N-termini of the proteins by amino acid sequencing confirmed the presence of the expected albumin sequence. Analysis of the purified proteins by electrospray mass spectrometry confirmed an increase in mass of 315 D (n= l), 630 D (n=2), 945 D (n=3) and 1260 D (n=4) compared to the HSA-hGH fusion protein described in Example 3, as expected. The purified protein was found to be active in vitro.
References
Cunningham, B. C. et al (1991) Science 254, 821-825. de Vos, A. M. et al (1992) Science 255, 306-312. Ealey et al (1995) Growth Regulation 5, 36-44.
Gleeson et al (1986) J. Gen. Microbiol. 132, 3459-3465.
Haffner, D. et al, (1994) J. Clin. Invest. 93, 1163-1171.
Hiramitsu et al (1990) App. Env. Microbiol. 56, 2125-2132.
Hiramitsu et al (1991) ibid 57, 2052-2056. Hoffman and Winston (1990) Genetics 124, 807-816.
Kearns, G. L. et al (1991) 7. Clin. Endocrinol. Metab. 72, 1148-1156.
Kunkel, T. A. et al (1987) Methods in Enzymol. 154, 367-382.
Martial, J. A. et al (1979) Science 205, 602-607.
Maundrell (1990) 7. Biol. Chem. 265, 10857-10864. Nomura, N. et al (1995) Biosci. Biotech. Biochem. 59, 532-534.
Poznansky, M. J. et al (1988) FEBS Lett. 239, 18-22.
Saiki et al (1988) Science 239, 487-491.
Sambrook, J. et al (1989) Molecular Cloning: a Laboratory Manual, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Sleep, O. et al (1990) Bio/Technology 8, 42-46.
Strobl, J. S. and Thomas, M. J. (1994) Pharmacol. Rev. 46, 1-34.
Tokunaga, T. et al (1985) Gene 39, 117-120.
Tsiomenko, A. B. et al (1994) Biochemistry (Moscow) 59, 1247-1256. Zeisel, H. J. et al (1992) Horm. Res. 37 (Suppl. 2), 5-13.

Claims

1. A polypeptide consisting of a continuous region of amino acids joined together by peptide bonds and comprising a first region of at least 10 amino acids which has at least 75% sequence identity with a same- length region of growth hormone (GH) and a second region of at least 10 amino acids which has at least 75 % sequence identity with a same-length region of serum albumin.
2. A polypeptide according to Claim 1 in which each of said first and second regions has at least 95 % sequence identity with the said lengths of GH and albumin, respectively.
3. A polypeptide according to Claim 2 wherein each of said first and second regions is at least 50 amino acids long.
4. A polypeptide according to any one of the preceding claims wherein the first region consists of uninterrupted amino acids of the C-terminus of GH, or a conservative modification thereof, and the polypeptide binds and activates the GH receptor.
5. A polypeptide according to Claim 4 wherein the first region is 191 amino acids long.
6. A polypeptide according to any one of the preceding claims wherein the albumin and/or the growth hormone is human.
7. A polypeptide according to any one of the preceding claims wherein the second region comprises at least one uninterrupted domain of albumin or a conservative modification thereof.
8. A polypeptide according to Claim 7 wherein the second region comprises uninterrupted amino acids 1-105, 120-194, 195-291 , 316-387, 388-491, 512-585, 1-194, 195-387, 388-585, 1-387 or 195-585 of human albumin or a conservative modification thereof.
9. A polypeptide according to any one of the preceding claims wherein the N-terminus of the polypeptide comprises the said first region and the C-terminus comprises the said second region.
10. A polypeptide according to any one of Claims 1 to 8 wherein the N-terminus of the polypeptide comprises the said second region and the C-terminus comprises the said first region.
11. A polypeptide according to any one of the preceding claims which consists of the said first and second regions, optionally with further amino acids or other compounds added to either end of the polypeptide.
12. A microbial culmre medium comprising transformed cells and a polypeptide according to any one of the preceding claims.
13. A microbial culmre medium comprising a polypeptide according to any one of Claims 1 to 11.
14. A polynucleotide encoding a polypeptide according to any one of Claims 1 to 11.
15. A microbial host comprising a polynucleotide according to Claim 14 arranged for expression in the host.
16. A host according to Claim 15 wherein the polypeptide is secreted from the host.
17. A process for obtaining a polypeptide according to any one of Claims 1 to 11 comprising culturing a host according to Claim 15 or 16 and purifying the polypeptide.
18. A pharmaceutical formulation comprising a polypeptide according to any one of Claims 1 to 11 and a pharmaceutically acceptable carrier.
19. A method of treating a patient having a condition which is treatable with growth hormone, the method comprising administering to the patient a said-condition-alleviating, non-toxic amount of a polypeptide according to any one of Claims 1 to 11.
20. A method of increasing beyond normal the growth rate of, or ratio of lean meat to fat meat in, an animal comprising admmistering to the animal an effective amount of a polypeptide according to any one of Claims 1 to 11.
21. A process for producing growth hormone, comprising expressing a polynucleotide according to Claim 14 in a microbial host, preferably yeast, the polypeptide encoded thereby having a site between the said first and second regions which site is cleavable by an enzyme present in the host, or by any other enzyme, or chemically.
PCT/GB1996/003164 1995-12-30 1996-12-19 Recombinant fusion proteins to growth hormone and serum albumin WO1997024445A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK05077642T DK1681304T3 (en) 1995-12-30 1996-12-19 Recombinant growth hormone and serum albumin fusion proteins
EP96942515A EP0870039B1 (en) 1995-12-30 1996-12-19 Recombinant fusion proteins to growth hormone and serum albumin
DE69635903T DE69635903T2 (en) 1995-12-30 1996-12-19 RECOMBINANT FUSION PROTEIN WITH GROWTH HORMONE AND SERUM ALBUMIN
JP52409897A JP4063878B2 (en) 1995-12-30 1996-12-19 Recombinant fusion protein for growth hormone and serum albumin
AU11649/97A AU715210B2 (en) 1995-12-30 1996-12-19 Recombinant fusion proteins to growth hormone and serum albumin
CA2240292A CA2240292C (en) 1995-12-30 1996-12-19 Recombinant fusion proteins to growth hormone and serum albumin
KR1019980704914A KR19990076789A (en) 1995-12-30 1996-12-19 Recombinant Fusion Proteins with Growth Hormone and Serum Albumin
US09/984,010 US7045318B2 (en) 1995-12-30 2001-10-26 Recombinant fusion proteins to growth hormone and serum albumin
US11/315,035 US7550432B2 (en) 1995-12-30 2005-12-23 Recombinant fusion proteins to growth hormone and serum albumin
US12/471,168 US8642542B2 (en) 1995-12-30 2009-05-22 Recombinant fusion proteins to growth hormone and serum albumin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526733.2A GB9526733D0 (en) 1995-12-30 1995-12-30 Fusion proteins
GB9526733.2 1995-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09091873 A-371-Of-International 1996-12-19
US09/984,010 Continuation US7045318B2 (en) 1995-12-30 2001-10-26 Recombinant fusion proteins to growth hormone and serum albumin

Publications (1)

Publication Number Publication Date
WO1997024445A1 true WO1997024445A1 (en) 1997-07-10

Family

ID=10786210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003164 WO1997024445A1 (en) 1995-12-30 1996-12-19 Recombinant fusion proteins to growth hormone and serum albumin

Country Status (15)

Country Link
US (3) US7045318B2 (en)
EP (2) EP0870039B1 (en)
JP (1) JP4063878B2 (en)
KR (1) KR19990076789A (en)
CN (2) CN1119421C (en)
AT (2) ATE413460T1 (en)
AU (1) AU715210B2 (en)
CA (1) CA2240292C (en)
DE (2) DE69637743D1 (en)
DK (2) DK0870039T3 (en)
ES (2) ES2264146T3 (en)
GB (1) GB9526733D0 (en)
HK (1) HK1066816A1 (en)
PT (2) PT1681304E (en)
WO (1) WO1997024445A1 (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0952158A1 (en) * 1996-10-24 1999-10-27 Universidad Autonoma de Nuevo Leon Modified methylotrophic p. pastoris yeast which secretes human groth hormone
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
EP1322667A2 (en) * 2000-08-25 2003-07-02 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6-alpha and 6-beta
WO2003070765A3 (en) * 2001-12-14 2003-11-27 Asterion Ltd Growth hormone fusion protein
WO2004005335A2 (en) * 2002-07-05 2004-01-15 Borean Pharma A/S Multimerised growth hormone fusion proteins
WO2004015113A2 (en) * 2002-08-07 2004-02-19 Delta Biotechnology Ltd. Albumin-fused ciliary neurotrophic factor
WO2003060071A3 (en) * 2001-12-21 2004-02-26 Human Genome Sciences Inc Albumin fusion proteins
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6946134B1 (en) * 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005100571A1 (en) * 2004-04-19 2005-10-27 Novo Nordisk A/S Osteogenic growth peptide fusion proteins
WO2006018428A2 (en) * 2004-08-20 2006-02-23 Novo Nordisk A/S Hemopexin fusion proteins
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1729795A2 (en) * 2004-02-09 2006-12-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
US7414107B2 (en) 1998-03-09 2008-08-19 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP2048234A1 (en) 1999-01-30 2009-04-15 Novozymes Biopharma UK Limited Chromatographic method for purification of albumin
WO2009058322A1 (en) 2007-10-31 2009-05-07 Human Genome Sciences, Inc. Albumin fusion proteins
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2080771A2 (en) 2001-02-27 2009-07-22 Maxygen Aps New interferon beta-like molecules
EP2090589A1 (en) 2002-02-07 2009-08-19 Dyax Corp. Albumin-fused Kunitz domain peptides
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP2163626A1 (en) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
US7977306B2 (en) 2001-12-21 2011-07-12 Human Genome Sciences, Inc. Albumin fusion proteins
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8034618B2 (en) 2001-12-18 2011-10-11 Eldgenossische Technische Hochschule Zurich PTH containing cell growth matrix
EP2390333A1 (en) 2002-07-23 2011-11-30 Novozymes Biopharma DK A/S Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
WO2012041981A2 (en) 2010-09-30 2012-04-05 Laboratorios Del Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
US8226942B2 (en) 2007-12-28 2012-07-24 Kuros Biosurgery Ag PDGF fusion proteins incorporated into fibrin foams
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
US8575104B2 (en) 2008-06-24 2013-11-05 Csl Behring Gmbh Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
US8642542B2 (en) 1995-12-30 2014-02-04 Novozymes Biopharma Dk A/S Recombinant fusion proteins to growth hormone and serum albumin
US8765915B2 (en) 2006-02-06 2014-07-01 Csl Behring Gmbh Modified coagulation factor VIIa with extended half-life
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2016065326A2 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US9873746B2 (en) 2003-10-22 2018-01-23 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US9878017B2 (en) 2013-04-22 2018-01-30 Csl Ltd. Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
US20190010205A1 (en) * 2016-03-14 2019-01-10 Jcr Pharmaceuticals Co., Ltd. Serum albumin-20k growth hormone fusion protein
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US10501524B2 (en) 2012-11-08 2019-12-10 Albumedix Ltd Albumin variants
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
US10654912B2 (en) 2015-09-08 2020-05-19 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
US10696732B2 (en) 2009-10-30 2020-06-30 Albumedix, Ltd Albumin variants
US10711050B2 (en) 2011-11-18 2020-07-14 Albumedix Ltd Variant serum albumin with improved half-life and other properties
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US12138296B2 (en) 2022-02-02 2024-11-12 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AUPP655698A0 (en) * 1998-10-16 1998-11-05 Commonwealth Scientific And Industrial Research Organisation Delivery system for porcine somatotropin
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
CN1405181A (en) * 2001-08-10 2003-03-26 中国人民解放军军事医学科学院生物工程研究所 Serum albumin and interferon fusion protein
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US20080167238A1 (en) * 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
CN1980687B (en) * 2004-02-09 2015-05-13 人类基因科学公司 Albumin fusion proteins
JP4492156B2 (en) * 2004-03-03 2010-06-30 ニプロ株式会社 Protein containing serum albumin domain
JP2008503233A (en) * 2004-06-23 2008-02-07 ユーエスブイ・リミテッド Chimeric human growth hormone derived from placenta and pituitary isoforms and method for obtaining the chimera
NZ584597A (en) * 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101384623B (en) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 Process for the production of preformed conjugates of albumin and a therapeutic agent
AU2007271150A1 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
MX2009002523A (en) 2006-09-08 2009-03-20 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their uses.
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US10457719B2 (en) 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
BRPI0921586A2 (en) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc human serum albumin articulators and conjugates thereof
NZ593833A (en) 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BRPI1010880A2 (en) * 2009-06-08 2019-10-01 Amunix Operating Inc growth hormone polypeptides and methods of making and using them.
JP2013502458A (en) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド Coagulation factor VII composition and methods of making and using the same
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
WO2011159777A2 (en) * 2010-06-16 2011-12-22 University Of Connecticut Chimeric cytokine of il-7 and alpha-chain of hgf and methods of use
EP3241558B1 (en) * 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
MX353816B (en) * 2011-05-05 2018-01-30 Albumedix As Albumin variants.
CA3132298A1 (en) 2011-06-28 2013-01-03 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102097263B1 (en) 2012-02-15 2020-04-06 바이오버라티브 테라퓨틱스 인크. Factor viii compositions and methods of making and using same
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
JP6124986B2 (en) 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Growth and differentiation factor (GDF) for treating diastolic heart failure
KR102434075B1 (en) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. Carriers for improved drug delivery
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2014113359A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
MX2015008944A (en) * 2013-01-15 2016-06-21 Teva Pharma Lyophilization process.
EP2968470B1 (en) 2013-03-12 2020-10-28 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
DK3524618T5 (en) 2013-03-15 2024-09-02 Gladiator Biosciences Inc GLA DOMAINS AS TARGETING AGENTS
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US20160220640A1 (en) 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CA3151082A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10456445B2 (en) 2014-06-02 2019-10-29 Children's Medical Center Corporation Methods and compositions for immunomodulation
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
BR112018003794A2 (en) 2015-08-27 2018-09-25 Massachusetts Inst Technology pain treatment compositions and methods
US20200407421A1 (en) 2017-09-05 2020-12-31 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CN109851674B (en) * 2018-10-26 2022-02-15 天津林达生物科技有限公司 Preparation and purification method of recombinant human serum albumin/growth hormone fusion protein for treating children's dwarf syndrome
KR20220083784A (en) 2019-10-17 2022-06-20 제이씨알 파마 가부시키가이샤 Method for producing a fusion protein of serum albumin and growth hormone
CN114728043B (en) * 2019-10-30 2024-04-16 Jcr制药股份有限公司 Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
US20230241171A1 (en) 2020-07-10 2023-08-03 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
CN118420785A (en) * 2024-05-29 2024-08-02 武汉软件工程职业学院(武汉开放大学) Human growth hormone fusion protein and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
EP0319641A1 (en) * 1987-12-02 1989-06-14 Green Cross Corporation Method for preparing foreign protein in yeast, recombinat DNA, transformant
EP0399666A1 (en) * 1989-04-29 1990-11-28 Delta Biotechnology Limited Fusion proteins containing N-terminal fragments of human serum albumin
US5045312A (en) * 1985-02-18 1991-09-03 Burroughs Wellcome Co. Physiologically active compositions of growth hormone and serum albumin or Ig G
WO1993015199A1 (en) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides
WO1995030759A1 (en) * 1994-05-06 1995-11-16 Rhone-Poulenc Rorer S.A. Biologically active polypeptides inserted into an albumin

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2449885C3 (en) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
IL66614A (en) 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
EP0079739A3 (en) 1981-11-12 1984-08-08 The Upjohn Company Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en) 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4595658A (en) * 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
JPS6087792A (en) 1983-09-23 1985-05-17 ジェネックス・コーポレイション Variant control region
GB8334261D0 (en) 1983-12-22 1984-02-01 Bass Plc Fermentation processes
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2579224B1 (en) 1985-03-25 1987-05-22 Genetica PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
US4894332A (en) 1985-03-27 1990-01-16 Biogen, Inc. DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
EP0196056B1 (en) 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
EP0206733A1 (en) 1985-06-17 1986-12-30 Genex Corporation Cloned human serum albumin gene
JPS6296086A (en) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol Composite plasmid
US5641663A (en) 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (en) 1987-07-21 1992-02-11 Robert T. Garvin Characterization and structure of genes for protease a and protease b from streptomyces griseus
FR2594846B1 (en) 1986-02-21 1989-10-20 Genetica PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
IT1203758B (en) 1986-03-27 1989-02-23 Univ Roma CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
EP0301670B2 (en) 1987-07-28 2000-06-14 Gist-Brocades N.V. Kluyveromyces as a host strain
SE459586B (en) 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JPH0811074B2 (en) 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
PT89484B (en) 1988-01-22 1994-03-31 Gen Hospital Corp GENE CLONED CODES OF FUSAO PROTEINS IG-CD4 AND ITS UTILIZATION
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
DE68925893T2 (en) * 1988-07-23 1996-08-08 Delta Biotechnology Ltd SECRETORIC LEADER SEQUENCES
FR2635115B1 (en) 1988-08-05 1992-04-03 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH02227079A (en) 1988-10-06 1990-09-10 Tonen Corp Human serum albumin fragment
US5298243A (en) 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (en) 1988-10-26 1990-05-01 Tonen Corp Production of human serum albumin a by yeast host
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
EP0395918A3 (en) 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE125869T1 (en) 1989-06-09 1995-08-15 Gropep Pty Ltd GROWTH HORMONE FUSION PROTEINS.
JPH0327320A (en) 1989-06-26 1991-02-05 Ajinomoto Co Inc Human b cell differentiation factor pharmaceutical composition
JP2794306B2 (en) 1989-07-04 1998-09-03 ティーディーケイ株式会社 Magnetic garnet material and Faraday rotating element
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
CU22222A1 (en) 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DK608589D0 (en) 1989-12-01 1989-12-01 Holm Arne CHEMICAL PROCEDURE
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
JPH03201987A (en) 1989-12-29 1991-09-03 Tonen Corp Human serum albumin fragment
JPH04211375A (en) 1990-02-05 1992-08-03 Ajinomoto Co Inc Synthetic gene and production of human serum albumin using the synthetic gene
DE4005874A1 (en) * 1990-02-24 1991-11-07 Boehringer Mannheim Gmbh CARRIER-TIED RECOMBINANT PROTEINS, METHOD FOR THE PRODUCTION AND USE AS IMMUNOGENIC AND VACCINE
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
JPH07108232B2 (en) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 Method for producing peptide or protein
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en) 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
EP0509841A3 (en) 1991-04-18 1993-08-18 Tonen Corporation Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en) 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
FR2676070B1 (en) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa YEAST PROMOTER AND ITS USE.
US5646012A (en) 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
FR2677996B1 (en) 1991-06-21 1993-08-27 Rhone Poulenc Rorer Sa CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
AU665599B2 (en) 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (en) 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SE9201073D0 (en) 1992-04-03 1992-04-03 Kabi Pharmacia Ab PROTEIN FORMULATION
US5686268A (en) 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
FR2694294B1 (en) 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Yeast promoter and its user.
DE69329651T3 (en) * 1992-07-31 2008-10-30 Genentech, Inc., South San Francisco AQUEOUS MEDICINE COMPOSITION CONTAINING HUMAN GROWTH HORMONE
DE4226971C2 (en) 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modified fungal cells and processes for the production of recombinant products
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
FR2726471B1 (en) 1994-11-07 1997-01-31 Pf Medicament PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
FR2726576B1 (en) 1994-11-07 1997-01-31 Pf Medicament PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
AT403167B (en) 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
JPH0995455A (en) 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd Renal function improving agent
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU718254B2 (en) 1996-01-19 2000-04-13 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
EP0961832A4 (en) 1996-09-18 2003-02-26 Human Genome Sciences Inc Human tumor necrosis factor receptor-like genes
US7026447B2 (en) 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
CN1119352C (en) 1998-05-15 2003-08-27 中国科学院上海生物化学研究所 Express and purification of human serum albumin in pichia
CN1105727C (en) 1998-06-17 2003-04-16 上海海济医药生物工程有限公司 Process for preparing recombined human serum albumin
GB9817084D0 (en) 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US6546113B1 (en) * 1999-03-02 2003-04-08 Leitch Technology International Inc. Method and apparatus for video watermarking
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20020048571A1 (en) 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2446739A1 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
ES2567634T3 (en) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP2009504157A (en) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc Albumin fusion proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045312A (en) * 1985-02-18 1991-09-03 Burroughs Wellcome Co. Physiologically active compositions of growth hormone and serum albumin or Ig G
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
EP0319641A1 (en) * 1987-12-02 1989-06-14 Green Cross Corporation Method for preparing foreign protein in yeast, recombinat DNA, transformant
EP0399666A1 (en) * 1989-04-29 1990-11-28 Delta Biotechnology Limited Fusion proteins containing N-terminal fragments of human serum albumin
WO1993015199A1 (en) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides
WO1995030759A1 (en) * 1994-05-06 1995-11-16 Rhone-Poulenc Rorer S.A. Biologically active polypeptides inserted into an albumin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.B. TSIOMENKO ET AL.: "Prosegment of yeast alpha-factor directs a heterologous protein {Human Growth Hormone} to the culture medium of Saccharomyces cerevisiae.", BIOCHEMISTRY, vol. 59, no. 11, 1994, {MOSCOW}, pages 1247 - 1256, XP000618681 *
C.A. PINKERT ET AL.: "An albumin enhancer located 10kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice.", GENES AND DEVELOPMENT, vol. 1, no. 3, May 1987 (1987-05-01), pages 268 - 76, XP000618715 *
M.J. POZNANSKY ET AL.: "Growth hormone-albumin conjugates.", FEBS LETT, vol. 239, no. 1, October 1988 (1988-10-01), pages 18 - 22, XP000645058 *
R. HIRAMATSU ET AL.: "The prepro-peptide of Mucor rennin directs the secretion of human growth hormone by Saccharomyces cerevisiae.", APP. ENVIRON. MICROBIOL., vol. 56, no. 7, July 1990 (1990-07-01), pages 2125 - 2132, XP000618730 *

Cited By (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642542B2 (en) 1995-12-30 2014-02-04 Novozymes Biopharma Dk A/S Recombinant fusion proteins to growth hormone and serum albumin
EP0952158A4 (en) * 1996-10-24 2001-10-24 Univ Autonoma De Nuevo Leon Modified methylotrophic p. pastoris yeast which secretes human groth hormone
EP0952158A1 (en) * 1996-10-24 1999-10-27 Universidad Autonoma de Nuevo Leon Modified methylotrophic p. pastoris yeast which secretes human groth hormone
US7414107B2 (en) 1998-03-09 2008-08-19 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7935786B2 (en) 1998-03-09 2011-05-03 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
EP2048234A1 (en) 1999-01-30 2009-04-15 Novozymes Biopharma UK Limited Chromatographic method for purification of albumin
EP2272961A1 (en) 1999-01-30 2011-01-12 Novozymes Biopharma DK A/S Process for producing recombinant albumin with reduced mannosylation
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US7259248B2 (en) 1999-11-18 2007-08-21 Chiron Corporation Human FGF-21 polypeptides
EP2163626A1 (en) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
US7723297B2 (en) 1999-11-18 2010-05-25 Kyoto University Human FGF-21 gene and gene expression products
US20120141449A1 (en) * 2000-04-12 2012-06-07 Delta Biotechnology Limited Albumin Fusion Proteins
EP2311872A1 (en) 2000-04-12 2011-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US9775888B2 (en) 2000-04-12 2017-10-03 Albumedix A/S Treatment with factor ix-albumin fusion protein
US9849162B2 (en) 2000-04-12 2017-12-26 Albumedix A/S Treatment with factor VII-albumin fusion protein
US8946156B2 (en) 2000-04-12 2015-02-03 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1274719A4 (en) * 2000-04-12 2004-05-19 Human Genome Sciences Inc Albumin fusion proteins
EP1276756A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
EP1276849A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
EP1276856A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
EP2216409A1 (en) 2000-04-12 2010-08-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
EP1278544A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
US10080785B2 (en) 2000-04-12 2018-09-25 Novozymes Biopharma Dk A/S Albumin fusion proteins
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6905688B2 (en) * 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) * 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US6994857B2 (en) * 2000-04-12 2006-02-07 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001079271A1 (en) * 2000-04-12 2001-10-25 Principia Pharmaceutical Corporation Albumin fusion proteins
EP2357008A1 (en) 2000-04-12 2011-08-17 Human Genome Sciences, Inc. Albumin fusion proteins
EP1278544A2 (en) * 2000-04-12 2003-01-29 Human Genome Sciences, Inc. Albumin fusion proteins
US9821039B2 (en) 2000-04-12 2017-11-21 Albumedix A/S Albumin fusion proteins
EP1276856A1 (en) * 2000-04-12 2003-01-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7785599B2 (en) * 2000-04-12 2010-08-31 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274719A2 (en) * 2000-04-12 2003-01-15 Human Genome Sciences, Inc. Albumin fusion proteins
EP2298355A2 (en) 2000-04-12 2011-03-23 Human Genome Sciences, Inc. Albumin fusion proteins
EP2236152A1 (en) 2000-04-12 2010-10-06 Human Genome Sciences, Inc. Albumin fusion proteins
EP1276849A2 (en) * 2000-04-12 2003-01-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1983055A1 (en) * 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2295456A1 (en) 2000-04-12 2011-03-16 Human Genome Sciences, Inc. Albumin fusion proteins
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1276756A1 (en) * 2000-04-12 2003-01-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A1 (en) * 2000-04-12 2003-01-15 Human Genome Sciences, Inc. Albumin fusion proteins
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
EP1322667A2 (en) * 2000-08-25 2003-07-02 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6-alpha and 6-beta
EP1322667A4 (en) * 2000-08-25 2004-08-18 Human Genome Sciences Inc Tumor necrosis factor receptors 6-alpha and 6-beta
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
EP2080771A2 (en) 2001-02-27 2009-07-22 Maxygen Aps New interferon beta-like molecules
US7524649B2 (en) 2001-12-14 2009-04-28 Asterion Limited Modified growth hormone fusion polypeptides
KR100879553B1 (en) * 2001-12-14 2009-01-22 아스테리온 리미티드 Modified polypeptide
KR100848802B1 (en) 2001-12-14 2008-07-28 아스테리온 리미티드 Modified polypeptide
EP2365085A1 (en) * 2001-12-14 2011-09-14 Asterion Limited Growth hormone fusion protein
SG160205A1 (en) * 2001-12-14 2010-04-29 Asterion Ltd Modified polypeptide
WO2003070765A3 (en) * 2001-12-14 2003-11-27 Asterion Ltd Growth hormone fusion protein
US8034618B2 (en) 2001-12-18 2011-10-11 Eldgenossische Technische Hochschule Zurich PTH containing cell growth matrix
EP2277888A2 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
US7141547B2 (en) * 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US8211439B2 (en) 2001-12-21 2012-07-03 Human Genome Sciences, Inc. Albumin fusion proteins comprising insulin polypeptides
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250A1 (en) 2001-12-21 2010-12-15 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A3 (en) * 2001-12-21 2004-02-26 Human Genome Sciences Inc Albumin fusion proteins
JP2005514060A (en) * 2001-12-21 2005-05-19 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Albumin fusion protein
US9296809B2 (en) 2001-12-21 2016-03-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277889A2 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US7977306B2 (en) 2001-12-21 2011-07-12 Human Genome Sciences, Inc. Albumin fusion proteins
US8993517B2 (en) 2001-12-21 2015-03-31 Human Genome Sciences, Inc. Albumin fusion proteins
US7799759B2 (en) 2001-12-21 2010-09-21 Human Genome Sciences, Inc. Albumin fusion proteins
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
US9221896B2 (en) 2001-12-21 2015-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP2090589A1 (en) 2002-02-07 2009-08-19 Dyax Corp. Albumin-fused Kunitz domain peptides
WO2004005335A2 (en) * 2002-07-05 2004-01-15 Borean Pharma A/S Multimerised growth hormone fusion proteins
WO2004005335A3 (en) * 2002-07-05 2004-02-26 Borean Pharma As Multimerised growth hormone fusion proteins
EP2390333A1 (en) 2002-07-23 2011-11-30 Novozymes Biopharma DK A/S Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield
WO2004015113A2 (en) * 2002-08-07 2004-02-19 Delta Biotechnology Ltd. Albumin-fused ciliary neurotrophic factor
WO2004015113A3 (en) * 2002-08-07 2004-05-06 Aventis Behring Gmbh Albumin-fused ciliary neurotrophic factor
US11447560B2 (en) 2003-10-22 2022-09-20 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US10259883B2 (en) 2003-10-22 2019-04-16 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US10155819B2 (en) 2003-10-22 2018-12-18 Alderbio Holdings Llc Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US9873746B2 (en) 2003-10-22 2018-01-23 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1729795A4 (en) * 2004-02-09 2008-05-21 Human Genome Sciences Inc Albumin fusion proteins
US7569384B2 (en) 2004-02-09 2009-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1729795A2 (en) * 2004-02-09 2006-12-13 Human Genome Sciences, Inc. Albumin fusion proteins
US8143026B2 (en) 2004-02-09 2012-03-27 Human Genome Sciences, Inc. Albumin fusion proteins
AU2005211725B2 (en) * 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005100571A1 (en) * 2004-04-19 2005-10-27 Novo Nordisk A/S Osteogenic growth peptide fusion proteins
WO2006018428A2 (en) * 2004-08-20 2006-02-23 Novo Nordisk A/S Hemopexin fusion proteins
WO2006018428A3 (en) * 2004-08-20 2006-06-08 Novo Nordisk As Hemopexin fusion proteins
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US8765915B2 (en) 2006-02-06 2014-07-01 Csl Behring Gmbh Modified coagulation factor VIIa with extended half-life
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
US8969538B2 (en) 2006-06-07 2015-03-03 Human Genome Sciences, Inc. Albumin fusion proteins
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US11993637B2 (en) 2007-03-30 2024-05-28 Ambrx, Inc. Modified FGF-21 polypeptides with non-naturally encoded amino acids
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
WO2009058322A1 (en) 2007-10-31 2009-05-07 Human Genome Sciences, Inc. Albumin fusion proteins
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US8226942B2 (en) 2007-12-28 2012-07-24 Kuros Biosurgery Ag PDGF fusion proteins incorporated into fibrin foams
US9290561B2 (en) 2008-06-24 2016-03-22 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
US8575104B2 (en) 2008-06-24 2013-11-05 Csl Behring Gmbh Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP3225248A1 (en) 2008-07-23 2017-10-04 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP3243835A1 (en) 2009-02-11 2017-11-15 Albumedix A/S Albumin variants and conjugates
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
US11555061B2 (en) 2009-02-11 2023-01-17 Albumedix, Ltd Albumin variants and conjugates
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
US10696732B2 (en) 2009-10-30 2020-06-30 Albumedix, Ltd Albumin variants
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP4302783A2 (en) 2010-08-17 2024-01-10 Ambrx, Inc. Modified relaxin polypeptides and their uses
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012041981A2 (en) 2010-09-30 2012-04-05 Laboratorios Del Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
US10155803B2 (en) 2011-03-03 2018-12-18 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US10711051B2 (en) 2011-03-03 2020-07-14 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US10711050B2 (en) 2011-11-18 2020-07-14 Albumedix Ltd Variant serum albumin with improved half-life and other properties
US10329340B2 (en) 2012-03-16 2019-06-25 Albumedix Ltd Albumin variants
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
US9388231B2 (en) 2012-07-13 2016-07-12 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US10358479B2 (en) 2012-07-13 2019-07-23 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US11248037B2 (en) 2012-07-13 2022-02-15 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
US10934341B2 (en) 2012-11-08 2021-03-02 Albumedix, Ltd. Albumin variants
US10501524B2 (en) 2012-11-08 2019-12-10 Albumedix Ltd Albumin variants
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US9878017B2 (en) 2013-04-22 2018-01-30 Csl Ltd. Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
WO2016065326A2 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
EP3412302A1 (en) 2014-10-24 2018-12-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
US12116400B2 (en) 2015-08-20 2024-10-15 Sartorius Albumedix Limited Albumin variants and conjugates
US10654912B2 (en) 2015-09-08 2020-05-19 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
EP3845644A1 (en) * 2015-09-08 2021-07-07 JCR Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
US11046751B2 (en) 2015-09-08 2021-06-29 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
US11634474B2 (en) 2015-09-08 2023-04-25 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
EP4374913A3 (en) * 2015-09-08 2024-08-14 JCR Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
US10968267B2 (en) 2016-03-14 2021-04-06 Jcr Pharmaceuticals Co., Ltd. Serum albumin-20K growth hormone fusion protein
US20190010205A1 (en) * 2016-03-14 2019-01-10 Jcr Pharmaceuticals Co., Ltd. Serum albumin-20k growth hormone fusion protein
EP3431508A4 (en) * 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. Serum albumin-20 k growth hormone fusion protein
CN110770251A (en) * 2017-04-20 2020-02-07 诺和诺德股份有限公司 Method for purifying albumin fusion proteins
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
US12138296B2 (en) 2022-02-02 2024-11-12 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Also Published As

Publication number Publication date
PT1681304E (en) 2009-02-11
US20030104578A1 (en) 2003-06-05
DE69635903D1 (en) 2006-05-04
EP1681304A2 (en) 2006-07-19
EP1681304A3 (en) 2006-11-22
US7045318B2 (en) 2006-05-16
EP1681304B1 (en) 2008-11-05
CA2240292C (en) 2013-05-28
EP0870039A1 (en) 1998-10-14
ATE413460T1 (en) 2008-11-15
US20100261650A1 (en) 2010-10-14
CA2240292A1 (en) 1997-07-10
ATE319838T1 (en) 2006-03-15
HK1066816A1 (en) 2005-04-01
GB9526733D0 (en) 1996-02-28
PT870039E (en) 2006-07-31
AU715210B2 (en) 2000-01-20
ES2264146T3 (en) 2006-12-16
EP0870039B1 (en) 2006-03-08
US7550432B2 (en) 2009-06-23
CN1119421C (en) 2003-08-27
KR19990076789A (en) 1999-10-15
US20070299006A1 (en) 2007-12-27
AU1164997A (en) 1997-07-28
JP4063878B2 (en) 2008-03-19
ES2318418T3 (en) 2009-05-01
DE69635903T2 (en) 2006-11-16
DK1681304T3 (en) 2009-03-02
US8642542B2 (en) 2014-02-04
US20110281800A9 (en) 2011-11-17
JP2000502901A (en) 2000-03-14
CN1207131A (en) 1999-02-03
CN1515591A (en) 2004-07-28
CN100590133C (en) 2010-02-17
DE69637743D1 (en) 2008-12-18
DK0870039T3 (en) 2006-07-10

Similar Documents

Publication Publication Date Title
EP1681304B1 (en) Recombinant fusion proteins of growth hormone and serum albumin
US9505823B2 (en) Albumin-insulin fusion proteins
EP2216409B1 (en) Albumin fusion proteins
KR100380532B1 (en) Yeast strain
US6686179B2 (en) Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
KR20040089608A (en) HIV Inhibiting Proteins
US20120258072A1 (en) Interleukin-11 Fusion Proteins
WO2008052043A2 (en) Opioid receptor agonist fusion proteins
KR20070016106A (en) Interleukin-11 fusion proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96199466.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996942515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2240292

Country of ref document: CA

Ref document number: 2240292

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980704914

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996942515

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980704914

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980704914

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996942515

Country of ref document: EP